GE HealthCare’s Pristina Recon DL tool has received pre-market authorisation (PMA) from the US Food and Drug Administration (FDA).
Artificial intelligence (AI) is rapidly reshaping the landscape of leukemia diagnosis, offering new possibilities for earlier detection, more precise classification, and improved patient care, ...
AI-Driven Visual Intelligence forms a critical cornerstone of both computer vision and artificial intelligence, serving ...
Online language learning market exhibits robust expansion driven by rising consumer demand for personalized learning, remote ...
Abstract: Lung cancer is the most common cause of cancer-related mortality globally. Early diagnosis of this highly fatal and prevalent disease can significantly improve survival rates and prevent its ...
GE HealthCare (Nasdaq: GEHC) announced today that it has received FDA Premarket Authorization for Pristina Recon DL, an ...
Abstract: Facial recognition systems are widely used in various applications such as security, healthcare, and authentication, but face significant challenges in uncontrolled environments. Poor ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback